We are live on ! Find out more
EW icon

Edwards Lifesciences

1,083 hedge funds and large institutions have $41.1B invested in Edwards Lifesciences in 2020 Q3 according to their latest regulatory filings, with 124 funds opening new positions, 393 increasing their positions, 375 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 80

54% more call options, than puts

Call options by funds: $220M | Put options by funds: $142M

36% more funds holding in top 10

Funds holding in top 10: 1419 (+5)

17% more capital invested

Capital invested by funds: $35.1B → $41.1B (+$6.05B)

3% more funds holding

Funds holding: 1,0471,083 (+36)

1.06% more ownership

Funds ownership: 81.85%82.91% (+1.1%)

5% more repeat investments, than reductions

Existing positions increased: 393 | Existing positions reduced: 375

Holders
1,083
Holders Change
+36
Holders Change %
+3.44%
% of All Funds
21.85%
Holding in Top 10
19
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+35.71%
% of All Funds
0.38%
New
124
Increased
393
Reduced
375
Closed
80
Calls
$220M
Puts
$142M
Net Calls
+$77.4M
Net Calls Change
+$61M
Name Holding Trade Value Shares
Change
Change in
Stake
AWM
1076
Avior Wealth Management
Nebraska
$1K
CAM
1077
ClariVest Asset Management
California
$1K
MPWT
1078
MassMutual Private Wealth & Trust
Connecticut
$1K
Fidelity International
1079
Fidelity International
Bermuda
$1K +$468 +6 +50%
TFM
1080
TFC Financial Management
Massachusetts
$1K +$1.4K +18 New
BHB
1081
Bank Hapoalim BM
Israel
$684 -$58K -743 -8%
WIM
1082
Westside Investment Management
California
$95
SFFS
1083
Stonehage Fleming Financial Services
Jersey
-$43.5M -630,254 Closed
Two Sigma Investments
1084
Two Sigma Investments
New York
-$37.5M -480,521 Closed
Royal London Asset Management
1085
Royal London Asset Management
United Kingdom
-$29.6M -436,005 Closed
SGAM
1086
Smith Group Asset Management
Texas
-$22M -318,638 Closed
Squarepoint
1087
Squarepoint
New York
-$17.7M -256,741 Closed
GF
1088
Gabelli Funds
New York
-$12.8M -185,700 Closed
DHFB
1089
Dixon Hubard Feinour & Brown
Virginia
-$9.79M -126,489 Closed
QC
1090
Quadrature Capital
United Kingdom
-$4.85M -70,229 Closed
FA
1091
Faithward Advisors
Pennsylvania
-$4.34M -62,797 Closed
BC
1092
Brookfield Corp
Ontario, Canada
-$3.09M -44,738 Closed
AAMU
1093
AEGON Asset Management (UK)
United Kingdom
-$2.44M -35,337 Closed
Capstone Investment Advisors
1094
Capstone Investment Advisors
New York
-$2.75M -35,287 Closed
GI
1095
GAMCO Investors
Connecticut
-$2.35M -34,017 Closed
MCM
1096
Monument Capital Management
Virginia
-$2.21M -32,046 Closed
ECM
1097
ExodusPoint Capital Management
New York
-$2.28M -29,187 Closed
ESCM
1098
Echo Street Capital Management
New York
-$1.66M -24,023 Closed
N
1099
Natixis
France
-$1.55M -22,377 Closed
PAMP
1100
Polar Asset Management Partners
Ontario, Canada
-$1.35M -19,580 Closed

EW Hedge Fund Activity: Q3 2020 in Review

1,083 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2020, worth a combined $41.1B — up 17% from $35.1B a quarter earlier.

Buyers outnumbered sellers: 124 funds opened new EW positions and 80 closed out — a net gain of 44 holders — while 393 added to existing stakes and 375 trimmed.

The largest buyer was Jackson Square Partners, opening a new position worth an estimated $469M. The largest seller was Two Sigma Advisers, cutting an estimated $142M.

  • 1,083 institutional investors held Edwards Lifesciences (EW) as of Q3 2020, up from 1,047 in Q2 2020.
  • Funds reported $41.1B of Edwards Lifesciences stock for Q3 2020, up 17% quarter-over-quarter.
  • 124 funds opened new Edwards Lifesciences positions in Q3 2020 and 80 closed out, a net change of +44 holders.
  • The largest Edwards Lifesciences buyer in Q3 2020 was Jackson Square Partners, an estimated $469M added.
  • The largest Edwards Lifesciences seller in Q3 2020 was Two Sigma Advisers, an estimated $142M sold.

Based on aggregated 13F filings for Q3 2020.